Breast Cancer
Conditions
Keywords
stage IV breast cancer
Brief summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
Detailed description
OBJECTIVES: * To profile serum glycan biomarkers in women with metastatic stage IV breast cancer, healthy controls, and patients with noncancer medical illness. * To determine whether serial serum glycan biomarkers correlate with response of metastatic disease to treatment. OUTLINE: This is a multicenter study. Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods. Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
Interventions
OTHERHealthy Controls
One blood draw (2 teaspoons)
OTHERMetastatic Breast Cancer
Blood samples will be drawn every 3 months, for up to 18 months.
OTHERNon-cancer medical illness
One blood draw (2 teaspoons)
Sponsors
University of California, Davis
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
DISEASE CHARACTERISTICS: * Patient or participant at the Women's Health Clinic, the Internal Medicine Clinic, or at the UC Davis Cancer Center, meeting 1 of the following criteria: * Diagnosis of stage IV metastatic breast cancer, receiving active treatment with chemotherapy, endocrine therapy, or targeted therapy * Patients/participants without cancer * Healthy control being seen for annual exams, meeting the following criteria: * No chronic disease * Not on regular prescribed medications * Patient without cancer being seen in the Internal Medicine Clinic * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * Not pregnant or breast feeding * No other active cancer PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness | up to 18 months |
Secondary
| Measure | Time frame |
|---|---|
| Predictability of serial serum biomarkers in determining disease response and/or progression | Up to 18 months |
Countries
United States
Outcome results
None listed